Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been given a consensus recommendation of “Hold” by the nine analysts that are covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $8.24.

A number of equities research analysts have recently commented on the company. Wells Fargo & Company lowered their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. UBS Group lowered their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. HC Wainwright lowered their price objective on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, January 29th. Finally, Wedbush restated a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th.

Insider Buying and Selling at Zentalis Pharmaceuticals

In related news, insider Ingmar Bruns bought 20,000 shares of Zentalis Pharmaceuticals stock in a transaction on Thursday, February 6th. The stock was acquired at an average price of $2.28 per share, with a total value of $45,600.00. Following the acquisition, the insider now directly owns 36,629 shares of the company’s stock, valued at $83,514.12. This represents a 120.27 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jan Skvarka bought 60,000 shares of Zentalis Pharmaceuticals stock in a transaction on Friday, January 31st. The shares were bought at an average cost of $1.72 per share, with a total value of $103,200.00. Following the acquisition, the director now directly owns 149,551 shares in the company, valued at approximately $257,227.72. This represents a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Integral Health Asset Management LLC purchased a new position in shares of Zentalis Pharmaceuticals during the fourth quarter worth about $3,182,000. Verition Fund Management LLC grew its holdings in shares of Zentalis Pharmaceuticals by 172.1% during the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after purchasing an additional 951,500 shares in the last quarter. Almitas Capital LLC grew its holdings in shares of Zentalis Pharmaceuticals by 69.3% during the fourth quarter. Almitas Capital LLC now owns 1,626,896 shares of the company’s stock worth $4,929,000 after purchasing an additional 665,968 shares in the last quarter. Boxer Capital Management LLC purchased a new position in shares of Zentalis Pharmaceuticals during the fourth quarter worth about $1,364,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Zentalis Pharmaceuticals by 75.7% during the fourth quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company’s stock worth $2,605,000 after purchasing an additional 370,511 shares in the last quarter.

Zentalis Pharmaceuticals Price Performance

NASDAQ ZNTL opened at $1.77 on Friday. The stock has a market capitalization of $126.14 million, a price-to-earnings ratio of -0.71 and a beta of 1.75. Zentalis Pharmaceuticals has a one year low of $1.61 and a one year high of $16.27. The business’s fifty day moving average is $2.21 and its 200-day moving average is $2.95.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.